Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
154 Leser
Artikel bewerten:
(0)

Nasdaq Nordic: Nasdaq Stockholm Welcomes Asarina Pharma to First North

Stockholm, September 24, 2018- Nasdaq (Nasdaq: NDAQ) announces that the trading
in Asarina Pharma AB's shares (short name: ASAP) will commence today on Nasdaq
First North in Stockholm. Asarina Pharma belongs to the health care sector and
is the 57th company to be admitted to trading on Nasdaq's Nordic markets* in
2018. 

Asarina Pharma is a Swedish biotech company developing Sepranolone, the world's
first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other
menstrual-related conditions. Its product pipeline is built on over 40 years'
research into menstrual-related disorders like PMDD and menstrual migraine.
With its new family of GAMSA compounds (GABAA Modulating Steroid Antagonists),
the company aims to deliver a new generation of safe, targeted treatments for
still widely untreated conditions, and to become a leading specialty pharma
company in Women's Health. Asarina Pharma is headquartered in Solna, Sweden.
For more information, please visit www.asarinapharma.com. 

"We're confident that the integrity and dynamism of Nasdaq First North will
play an important part in helping us reach our business and medical goals,"
said Peter Norkild, CEO of Asarina Pharma. "We're delighted to be part of such
a vibrant, informed market. The capital and commitment our new shareholders
have already invested in us is highly valued, and we look forward to welcoming
even more as we move forward." 

"We welcome Asarina Pharma to our European growth market, Nasdaq First North,"
said Adam Kostyál, SVP and Head of European Listings, Nasdaq. "Asarina Pharma
joins our strong health care sector, and we look forward to supporting the
company with the visibility and investor exposure that comes with a Nasdaq
First North listing." 

Asarina Pharma AB has appointed Erik Penser Bank AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki,
Nasdaq Iceland and Nasdaq Stockholm. 



About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by
the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is
regulated as an alternative marketplace). It does not have the legal status as
an EU-regulated market. Companies at Nasdaq First North are subject to the
rules of Nasdaq First North and not the legal requirements for admission to
trading on a regulated market. The risk in such an investment may be higher
than on the main market. 

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing,
exchange technology, listing, information and public company services. Through
its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock market, its
technology powers more than 100 marketplaces in 50 countries, and 1 in 10 of
the world's securities transactions. Nasdaq is home to approximately 4,000
total listings with a market value of $14 trillion. To learn more, visit:
http://business.nasdaq.com 

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq
Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker
Services are respectively brand names for the regulated markets of Nasdaq
Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS,
Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB
and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq
Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq
Vilnius. 

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made
under the Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995. These statements include, but are not limited to, statements about
Nasdaq and its products and offerings. We caution that these statements are not
guarantees of future performance. Actual results may differ materially from
those expressed or implied in the forward-looking statements. Forward-looking
statements involve a number of risks, uncertainties or other factors beyond
Nasdaq's control. These factors include, but are not limited to factors
detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed
with the U.S. Securities and Exchange Commission. We undertake no obligation to
release any revisions to any forward-looking statements. 

Media Relations Contact: 
Erik Granström           
+46 8 405 78 07          
erik.granstrom@nasdaq.com
-------------------------
Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2018 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.